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risk	 factor	 for	 non‐alcoholic	 fatty	 liver	 disease	 (NAFLD)	 in	women3 
and	promotes	 lipid	accumulation	 in	 female	adipose	 tissue	as	well	 as	
systemic	 lipotoxicity.4	 Female‐to‐male	 gender	 reassignment	patients	
undergoing	 androgen	 therapy	 develop	 dyslipidemia	 and	 abnormal	
body	composition.5,6	Mirroring	this,	the	adverse	metabolic	phenotype	
















may	 be	 metabolically	 disadvantageous.2	 To	 our	 knowledge,	 how‐











Data	 from	 practices	 that	 use	 VISION	 Electronic	 Medical	 Record	
(EMR)	 are	 gathered,	 anonymized	 and	 released	 for	 research	 pur‐
pose.12	The	resulting	database,	The	Health	 Improvement	Network	
(THIN)	database	holds	data	on	demographic	characteristics,	clinical	




2.2 | Testosterone and sex hormone‐binding 
globulin (SHBG) measurements
Men	or	women	over	the	age	of	16	who	had	a	measurement	of	the	
serum	 concentration	 of	 testosterone	 or	 SHBG	 between	 1st	 of	
January	2000	and	15th	of	May	2016	were	eligible	to	take	part	in	the	
study.	Common	clinical	indications	for	these	measurements	include	
suspected	polycystic	ovary	syndrome	 (PCOS)	 in	women,	 infertility	






assess	 risk	 within	 the	 normal	 range,	 measurements	 were	 catego‐
rized	 by	 applying	 clinically	 relevant	 cut‐off	 points	 for	 serum	 con‐
centrations	 (nmol/L).3	 For	 women,	 testosterone	 was	 grouped	 as	
<1.0	nmol/L	(reference	group),	1.0‐1.49,	1.5‐1.99,	2.0‐2.49,	2.5‐2.99,	
3.0‐3.49	and	>3.5	nmol/L.	For	men,	the	groups	were	as	follows:	<7,	
7‐9.9,	 10.0‐14.9,	 15‐19.9,	 >20.0	nmol/L	 (reference	 group)	 nmol/L.	
For	both	sexes,	SHBG	was	categorized	as	>60.0	nmol/L	 (reference	
group),	 50.0‐59.9,	 40.0‐49.9,	 30.0‐39.9,	 20.0‐29.9	 and	<20	nmol/L.	
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comorbidities	 such	 as	 cardiovascular	 disease,	 hypertension	 and	
T2DM.18	Within	 the	database,	diagnostic	 codes	 for	T2DM	were	
identified	based	on	Read	codes,	 a	hierarchical	 coding	 system	 to	







Baseline	 data	 of	 each	 category	 in	 the	 serum	 testosterone	 and	
SHBG	cohorts	were	reported	separately	for	men	and	women	as	
mean	 (standard	deviation)	 or	median	 (interquartile	 range	 [IQR])	
as	 appropriate	 for	 continuous	 variables	 and	 as	 proportions	 for	
categorical	 variables.	 Crude	 Incidence	Rate	 Ratio	 (IRR)	 and	 ad‐
justed	 Incidence	 Rate	 Ratio	 (aIRR)	were	 calculated	 by	 applying	
Poisson	regression	offsetting	for	the	person‐years	of	follow‐up.	
Covariates	adjusted	 for	 in	 the	model	were	age,	BMI,	Townsend	
quintiles	 and	 smoking	 status.	 In	 women,	 an	 additional	 model	
included	 polycystic	 ovary	 syndrome	 (PCOS)	 as	 a	 covariate	 to	
explore	 if	 the	risk	of	T2DM	in	women	was	 independent	of	a	di‐
agnosis	of	PCOS.	 In	an	additional	 sensitivity	analysis,	when	ad‐
justing	 for	 PCOS.	We	 accepted	 the	 presence	 of	 hirsutism	 and	
anovulation	as	indicative	of	PCOS	given	that	the	diagnosis	is	un‐
derreported	in	primary	care.
Where	 missing	 data	 existed	 (BMI,	 Townsend	 or	 smoking),	 we	






















3.1 | Characteristics of the cohorts with serum 
testosterone and SHBG measurements
A	total	of	152	430	participants	in	the	cohort	with	available	serum	
testosterone	 measurement	 results	 (testosterone	 cohort;	 70	541	
men	and	81	889	women)	and	a	total	of	57	941	participants	(15	907	
men	and	42	034	women)	 in	 the	SHBG	cohort,	 both	derived	 from	
the	 THIN	 database,	met	 the	 inclusion	 criteria	 and	were	 included	
in	the	current	study.	Median	follow‐up	in	the	testosterone	cohort	
was	 3.3	years	 (IQR:1.5‐6.1)	 in	men	 and	3.2	 (IQR:1.3‐6.2)	 years	 in	
women.	 In	 the	 SHBG	 cohort,	median	 follow‐up	was	 2.8	 (1.3‐4.9)	
years	 in	men	 and	 2.8	 (1.2‐5.4)	 in	women.	 The	mean	 age	 for	men	































of	developing	T2DM	 in	 those	with	 testosterone	 levels	<	7	nmol/L,	
compared	to	the	reference	category	of	≥20	nmol/L	(aIRR	2.71,	95%	CI	
2.34‐3.14,	P	<	0.001,	Table	2).	However,	the	risk	of	T2DM	increased	
even	within	 the	normal	male	 testosterone	range	 (15‐19.99	nmol/L,	
aIRR	1.29,	95%	CI	1.13‐1.47,	P	<	0.001;	10‐14.99	nmol/L,	aIRR	1.90,	
95%	CI	1.68‐2.15,	P	<	0.001,	Table	2	&	Figure	1A,B).
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In	the	SHBG	cohort,	among	15	907	men	studied,	there	were	708	
cases	of	 incident	T2DM	during	 the	 follow‐up	period.	After	adjust‐




the	 risk	 was	 more	 than	 5‐fold	 higher	 in	 the	 group	 with	 SHBG	
<	20	nmol/L	(aIRR	5.74,	95%	CI	3.72‐8.87,	Table	2	&	Figure	1C,D).
3.3 | Association between sex hormones and T2D 
risk in women
Among	 81	889	 women	 with	 serum	 testosterone	 measurements,	
1282	 developed	 T2DM	 during	 the	 follow‐up	 period.	 After	 ad‐
justing	 for	 age,	 BMI,	 Townsend	 index	 and	 smoking	 status,	 T2DM	
aIRR	 tended	 to	 be	 higher	with	 increasing	 serum	 testosterone	 lev‐
els.	 The	 risk	 increased	 significantly	 for	 serum	 testosterone	 lev‐
els	>	1.5	nmol/L,	as	compared	to	reference	category	(<1	nmol/L),	and	
continued	 to	 increase	across	each	category	of	 serum	 testosterone	
concentrations	thereafter,	with	a	twofold	 increase	 in	risk	observed	











l/L	 had	 a	9‐fold	higher	 risk	 of	 developing	T2DM	compared	 to	 the	
reference	 category	 of	 ≥60	nmol/L	 (aIRR	 9.23,	 95%	 CI	 6.61‐12.88,	





3.4 | Analysis of sex hormones as a 
continuous variable
In	men,	 for	every	nmol/L	decrease	 in	 testosterone,	 the	 risk	of	
T2DM	increased	by	5%	(aIRR	1.05,	95%	CI	1.04‐1.06,	P	<	0.001).	
TA B L E  1  Baseline	characteristics	of	the	testosterone	and	SHBG	cohorts	stratified	by	sex
Characteristics
Men Women
Serum testosterone Serum SHBG Serum testosterone Serum SHBG
Population,	n	(%) 70	541	(46.28) 15	907	(27.45) 81	889	(53.72) 42	034	(72.55)
Age	(years),	mean	(SD) 51.6	(14.8) 51.7	(16.0) 33.2	(10.9) 32.1	(10.6)
Townsend	index	n	(%)
1	(least	deprived) 20	017	(28.38) 3997	(25.13) 18	470	(22.55) 8753	(20.82)
2 15	481	(21.95) 3427	(21.54) 15	688	(19.16) 7688	(18.29)
3 13	687	(19.40) 3033	(19.07) 17	043	(20.81) 8681	(20.65)
4 10	997	(15.59) 2565	(16.12) 15	295	(18.68) 8155	(19.40)
5	(most	deprived) 7374	(10.45) 2186	(13.74) 10	269	(12.54) 5955	(14.17)
Missing	or	implausible	data 2985	(4.23) 699	(4.39) 5124	(6.26) 2802	(6.67)
BMI	(kg/m2)	categorized,	n	(%)
<25 19	195	(27.21) 3995	(25.11) 32	519	(39.71) 15	975	(38.00)
25‐30 25	962	(36.80) 5817	(36.57) 16	849	(20.58) 8445	(20.09)
>30 14	502	(20.56) 3978	(25.01) 19	791	(24.17) 10	825	(25.75)
Missing	or	implausible	data 10	882	(15.43) 2117	(13.31) 12	730	(15.55) 6789	(16.15)
Smoking	status,	n	(%)
Non‐smokers 53	311	(75.57) 12	264	(77.10) 61	288	(74.84) 31	557	(75.07)
Smokers 15	325	(21.72) 3377	(21.23) 18	020	(22.01) 9312	(22.15)





Follow‐up	in	years,	median	(IQR) 3.3	(1.5‐6.1) 2.8	(1.3	‐	4.9) 3.2	(1.3‐6.2) 2.8	(1.2‐5.4)
     |  149O’REILLY Et aL.
In	women,	 for	 every	 nmol/L	 increase	 in	 testosterone,	 the	 risk	
of	 T2DM	 increased	 by	 10%	 (aIRR	 1.10,	 95%	 CI	 1.06‐1.14,	
P	<	0.001).	 In	the	analysis	of	SHBG,	for	every	nmol/L	decrease	
in	 SHBG	 the	 risk	 of	 T2DM	 increased	 by	 3%	 in	 both	 men	 and	
women	(aIRR	1.03,	95%	CI	1.03‐1.04,	P	<	0.001,	in	both	sexes).
3.5 | Free androgen index and risk of T2DM
Only	 40%	 women	 (n	=	34	578)	 and	 16%	 of	 men	 (n	=	12	178)	 had	
undergone	 a	 simultaneous	measurement	of	 serum	SHBG	and	 tes‐
tosterone.	Using	 these	 to	 calculate	 the	 free	 androgen	 index	 (FAI),	
we	 found	 that	FAI	was	positively	associated	with	 risk	of	T2DM	 in	







(Figure	S1;	Tables	S9‐S12).	 Increased	 aIRRs	 for	T2DM	were	noted	
TA B L E  2  Risk	of	incident	T2DM	according	to	the	category	of	serum	testosterone	and	SHBG	at	baseline
IRR (95% CI); P‐value
Adjusteda Adjustedb Adjustedc Adjustedd
Men
Serum	testosterone	concentration	categories	(nmol/L)
<7 3.82	(3.31‐4.41);	P	<	0.001 2.60	(2.25‐3.00);	P	<	0.001 2.71	(2.34‐3.14);	P	<	0.001
7‐9.99 3.70	(3.24‐4.22);	P	<	0.001 2.46	(2.15‐2.81);	P	<	0.001 2.57	(2.24‐2.94);	P	<	0.001
10‐14.99 2.40	(2.13‐2.71);	P	<	0.001 1.83	(1.62‐2.06);	P	<	0.001 1.90	(1.68‐2.15);	P	<	0.001
15‐19.99 1.45	(1.27‐1.66);	P	<	0.001 1.25	(1.09‐1.43);	P	=	0.001 1.29	(1.13‐1.47);	P	<	0.001
≥20 Ref Ref Ref
Serum	SHBG	concentration	categories	(nmol/L)
<20 8.23	(5.37‐12.63);	P	<	0.001 5.00	(3.24‐7.71);	P	<	0.001 5.74	(3.72‐8.87);	P	<	0.001
20‐29.99 4.30	(2.83‐6.53);	P	<	0.001 2.92	(1.91‐4.44);	P	<	0.001 3.20	(2.09‐4.87);	P	<	0.001
30‐39.99 3.33	(2.19‐5.08);	P	<	0.001 2.45	(1.60‐3.74);	P	<	0.001 2.61	(1.71‐3.99);	P	<	0.001
40‐49.99 1.56	(0.98‐2.50);	P	=	0.063 1.28	(0.80‐2.06);	P	=	0.298 1.36	(0.85‐2.17);	P	=	0.207
50‐59.99 1.07	(0.61‐1.87);	P	=	0.825 0.88	(0.50‐1.54);	P	=	0.654 0.91	(0.52‐1.60);	P	=	0.748
≥60 Ref Ref Ref
Women
Serum	testosterone	concentration	categories	(nmol/L)
<1 Ref Ref Ref Ref
1.0‐1.49 1.21	(1.02‐1.43);	P	=	0.030 1.12	(0.95‐1.33);	P	=	0.184 1.12	(0.94‐1.32);	P	=	0.204 1.11	(0.94‐1.32);	P	=	0.213
1.5‐1.99 1.45	(1.23‐1.70);	P	<	0.001 1.26	(1.07‐1.48);	P	=	0.005 1.23	(1.05‐1.45);	P	=	0.011 1.23	(1.04‐1.44);	P	=	0.013
2.0‐2.49 1.70	(1.42‐2.04);	P	<	0.001 1.34	(1.12‐1.61);	P	=	0.002 1.30	(1.08‐1.56);	P	=	0.005 1.28	(1.07‐1.54);	P	=	0.008
2.5‐2.99 2.07	(1.67‐2.58);	P	<	0.001 1.59	(1.27‐1.97);	P	<	0.001 1.53	(1.23‐1.90);	P	<	0.001 1.50	(1.20‐1.87);	P	<	0.001
3.0‐3.49 2.51	(1.90‐3.32);	P	<	0.001 1.74	(1.31‐2.30);	P	<	0.001 1.68	(1.27‐2.23);	P	<	0.001 1.62	(1.22‐2.15);	P	=	0.001
≥3.5 3.00	(2.36‐3.82);	P	<	0.001 2.09	(1.64‐2.67);	P	<	0.001 1.98	(1.55‐2.52);	P	<	0.001 1.89	(1.48‐2.42);	P	<	0.001
Serum	SHBG	concentration	categories	(nmol/L)
<20 19.76	(14.36‐27.21);	P	<	0.001 8.96	(6.42‐12.50);	P	<	0.001 9.23	(6.61‐12.88);	P	<	0.001 9.13	(6.53‐12.75);	P	<	0.001
20‐29.99 8.66	(6.29‐11.93);	P	<	0.001 4.45	(3.20‐6.19);	P	<	0.001 4.48	(3.22‐6.24);	P	<	0.001 4.44	(3.19‐6.18);	P	<	0.001
30‐39.99 4.66	(3.31‐6.57);	P	<	0.001 2.69	(1.90‐3.82);	P	<	0.001 2.70	(1.91‐3.84);	P	<	0.001 2.69	(1.90‐3.82);	P	<	0.001
40‐49.99 2.99	(2.04‐4.38);	P	<	0.001 2.05	(1.40‐3.02);	P	<	0.001 2.08	(1.41‐3.05);	P	<	0.001 2.07	(1.41‐3.05);	P	<	0.001
50‐59.99 1.64	(1.02‐2.64);	P	=	0.043 1.29	(0.80‐2.08);	P	=	0.295 1.29	(0.80‐2.07);	P	=	0.304 1.29	(0.80‐2.08);	P	=	0.301





































strated	 that	 increased	 serum	 testosterone	 was	 associated	 with	 a	












development	 of	metabolic	 dysfunction	 are	 provided	 by	 studies	 in	
women	with	polycystic	ovary	syndrome	(PCOS),	a	disorder	affecting	
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up	 to	 10%	 of	 the	 female	 population	 and	 primarily	 defined	 by	 the	
presence	 of	 hyperandrogenism	 and	 ovulatory	 dysfunction.25	 We	
















from	male	 cohorts	 treated	 with	 short‐term	 androgen	 deprivation	
therapy	 show	 that	 hypogonadism	 directly	 induces	 metabolically	
deleterious	changes	in	body	composition,	with	increases	in	weight	
and	 in	percentage	fat	body	mass.33	However,	studies	of	androgen	





tions	 considered	 physiologically	 normal,	 but	 below	 the	 reference	
group	of	20	nmol/L,	independent	of	age,	obesity	and	other	potential	
confounding	 factors.	However,	 our	 results	 do	 not	 imply	 endorse‐
ment	 of	 testosterone	 pharmacotherapy	 to	 restore	 circulating	 tes‐
tosterone	levels	above	20	nmol/L	in	otherwise	healthy	men.	Studies	
investigating	 a	 potential	 beneficial	 impact	 of	 androgen	 therapy	
on	 metabolic	 outcomes	 in	 men	 with	 testosterone	 concentrations	
in	the	 low	or	 low‐normal	range	have	shown	at	best	conflicting	re‐
sults.	A	recent	double‐blind	placebo‐controlled	trial	of	testosterone	
treatment	 in	788	older	men	 showed	no	 impact	 on	 serum	glucose	
or	HbA1C34;	another	study	showed	no	change	in	insulin	sensitivity	
after	 36	months	 of	 treatment	 in	 308	 community‐dwelling	 men.35 
The	2018	Endocrine	Society	Clinical	Practice	Guideline	on	testos‐
terone	 therapy	 in	men	with	 hypogonadism	no	 longer	 recommend	
screening	men	with	T2DM	for	low	serum	testosterone,	and	advise	
against	using	testosterone	therapy	to	improve	glycaemic	control.36
Low	 circulating	 SHBG	 has	 been	 consistently	 identified	 as	 a	
surrogate	marker	 for	T2DM	in	both	sexes	 in	a	number	of	smaller	
studies	 and	 meta‐analyses,9,37,38	 and	 our	 study	 supports	 these	
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mediator	 of	 the	 association	 between	 sex	 steroids	 and	metabolic	
dysfunction.	The	majority	of	 circulating	 testosterone	 is	bound	 to	
SHBG,	 such	 that	 only	 the	 unbound	 or	 “free”	 fraction	 is	 capable	
of	 exerting	 effects	 in	 target	 tissues.39	 Therefore,	 reduced	 SHBG	
levels	 in	 women	 are	 a	 surrogate	 marker	 of	 increased	 circulating	
active	 androgens.	 Insulin	 is	 a	 potent	 regulator	 of	 hepatic	 SHBG	
























nificant	analytical	 and	quantification	difficulties	 for	 standard	RIAs,	
the	 consensus	 is	 that	 today	 measurements	 should	 be	 performed	











In	conclusion,	 in	the	 largest	retrospective	 longitudinal	study	of	






that	 women	 with	 androgen	 excess	 and	 men	 with	 androgen	 defi‐
ciency	should	be	systematically	screened	for	T2DM.	Future	studies	
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